Recent data report an important role of testosterone (T) in modulating female sexual responses, but little is known about the expression and distribution of androgen receptor (AR) in the human vagina. Therefore, the aims of our study were to evaluate the expression of AR in the human vagina in premenopausal (PrM) and menopausal (M) women and in T-treated women. Vaginal biopsies were obtained from PrM and postmenopausal women and from women with gender identity disorder (female to male (FtM)) receiving exogenous T. AR gene and protein expression levels in vaginal tissues were determined by real-time PCR and western blot analysis, respectively, whereas the localization of AR in vaginal mucosa and stroma was performed by immunohistochemistry. ARs were detected by immunostaining both in the mucosa and stroma. In vaginal mucosa, AR density score decreases with age but does not change with T administration. In stromal tissue, AR density score does not change with age but significantly increases with T administration (Po0.01). AR protein expression was significantly increased in FtM subjects (Po0.001). The expression of AR messenger RNA (mRNA) evaluated by Real-time PCR showed a significantly higher mRNA expression in FtM versus M patients (Po0.01) and in PrM versus M subjects (Po0.05). In conclusion, we found AR protein and mRNA expression both in the epithelium and stroma of the human vagina in all groups of women. A negative correlation exists between age and AR expression in the vaginal mucosa. T administration increases AR expression in both the mucosa and stroma.
INTRODUCTION
Vaginal mucosa is an organ sensible to steroid hormones, and the effects of estrogens (E) on vaginal tissue have been extensively studied.
1,2 The vagina is not generally considered an androgendependent organ, and the role of testosterone (T) on the physiological structuring and function of vaginal mucosae and the consequences of changes in T levels throughout the years and in different pathophysiological conditions have been poorly studied. Evidence accumulated in recent years, especially from animal studies, suggests that androgens may have a direct effect on vaginal structure and function, which are, at least partially, independent from estradiol. 3 Low T levels in aging women, as well as in other conditions such as after ovariectomy, are associated with a decline in sexual arousal, genital sensation, libido and orgasm, which are not restored by E replacement alone. 4 Exogenous T administration in these women improves different aspects of sexual function such as desire, libido and arousal. 5 In addition to these central effects, T administration may also have vaginal effects. 6--8 Androgen receptors (AR) have been detected in the human vagina by immunohistochemistry, suggesting a direct effect of T on vaginal tissue. 9 The detection of aromatase in the vaginal epithelium also suggests an indirect effect through the conversion to E. 9--11 Various animal studies have investigated the modulation of AR expression in physiological conditions and after sex steroid hormone administration in the vagina, 11--13 whereas data on human studies are scarce. Therefore, the aims of our study were as follows: (1) to confirm the presence of AR in the human vagina; (2) to evaluate the expression of receptors in different parts of the vagina and in the different layers of the vaginal mucosae; (3) to evaluate whether age affects vaginal AR density; and (4) to evaluate the effect of T administration on the expression of AR in premenopausal women. This work was carried out in parallel with the examination of histology, proliferation and innervation of the human vagina. The results of the parallel study will be reported in a separate paper owing to the large amount of data gathered.
MATERIALS AND METHODS
Specimens of vaginal mucosa were obtained from women undergoing vaginal surgery for pelvic organ prolapse or gender identity disorder called female to male (FtM). FtM undergo hysterectomy with salpingooophorectomy and vaginectomy for gender reassignment surgery. 14 All patients were divided into three groups: premenopausal women (PrM), FtM subjects and menopausal women (M). FtM subjects received hormonal treatment (100 mg Testoviron depot i.m. every 7--10 days) for at least 1 year before surgery. When included in the study, all FtM subjects were taking T and were at different time intervals from their last injection.
Exclusion criteria for PrM and M groups included history of malignancies, recent pregnancy (o3 years), previous ovariectomy or ovarian resection and any hormone intake for at least 1 year. Inclusion criteria for all women were the absence of major medical illness including oncological problems assessed by medical history and routine laboratory tests, and with regular medication intake in the previous 6 months.
Vaginal specimens were identified by the surgeon in the theater and classified as follows: proximal vagina, anterior and posterior; distal vagina, anterior and posterior. Specimens measured B1 cm by 1 cm, and included both the epithelium and stroma.
The specimens were divided into two portions: one was frozen for biomolecular analysis and the other was fixed in 4% formaldehyde for histological analysis and immunohistochemistry.
This study was approved by the Human Subject Committee of S. Orsola--Malpighi Hospital. Specimens were obtained with written Informed Consent.
Immunohistochemistry
Formalin-fixed, paraffin-embedded vaginal tissue samples were cut into 4-mm sections. After deparaffinization and inhibition of endogenous peroxidase activity, slides were subjected to antigen retrieval in citrate buffer (pH 6) and were then incubated with 10% normal goat serum for 45 min. Sections were stained overnight at 4 1C with mouse monoclonal antiandrogen receptor antibody (1:50; Dako Cytomation, Glostrup, Denmark). The primary antibody was revealed using goat anti-mouse immunoglobulins conjugated to peroxidase (EnVision, Dako Cytomation) and 3,3 0 -diaminobenzidine (DAB; Sigma-Aldrich Inc, Milan, Italy) as chromogen. In the negative controls, the immunostaining was performed without the primary antibody.
Section evaluations were performed at a magnification of Â 20, using an image cytometer consisting of a single 2/3'' CCD color camera (JVC Professional Europe, London, UK) mounted on a microscope (DMLB microscope, Leica Microsystems, Wetzlar, Germany) equipped with a motorized scanning table (Märzhäuser, Wetzlar, Germany) controlled by the Cytometrica software (C&V, Bologna, Italy). An Allred score was used to rate the immunostaining in each sample. The proportion of immunoreactive cells in the vaginal mucosa and stroma was assessed using the following scale: 1 ¼ no/few positive cells, 2 ¼ 5--10% of positive cells, 3 ¼ 30% of positive cells, 4 ¼ 50% of positive cells and 5 ¼ more than 50% of positive cells. Stain intensity was graded with the following scale: 1 ¼ weak, 2 ¼ moderate and 3 ¼ strong. The Allred score is obtained from the addition of the percentage score and the intensity score. 15 The total score for each sample was obtained from the addition of the Allred score from four different random fields.
Western blot
Vaginal tissue biopsies were homogenized in 1% Triton X-100 lysis buffer supplemented with a cocktail of protease inhibitors (NaCl 0.1 mol l
À1
, TrisHCl 0.01 mol l À1 pH 7.6, EDTA 0.001 mol l À1 , 1% Triton X-100, leupeptin 10 mg ml À1 , pepstatin 1 mg ml
, aprotinin 2 mg ml
, antipain 2 mg ml À1 , PMSF 100 ng ml
). Total protein concentration in each sample was determined by the Lowry method. Thereafter, 100 mg of total protein for each sample was electrophoresed on 8% sodium dodecyl sulfate polyacrylamide gels (8% polyacrylamide; 10% sodium dodecyl sulfate) under denaturing conditions (5% b-mercaptoethanol) and then transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA); as positive control, an equal amount of LNCap cell lysate was loaded on the gel. Membranes were blocked with 5% nonfat dry milk in 0.1% PBS-Tween and incubated overnight at 4 1C with rabbit polyclonal anti-androgen receptor antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA). The membranes were then washed three times with 0.1% PBS-Tween and incubated with anti-rabbit horseradish peroxidase secondary antibody. After thorough washing, the signal was detected by incubating the membranes with a peroxide and luminol enhancer solution (ECL-Advance, Amersham Biosciences, Piscataway, NJ, USA), after which they were exposed to autoradiographic film (ECL-Hyperfilm, Amersham Biosciences). Densitometry on the scanned film was performed using the NIH ImageJ software (http:// rsbweb.nih.gov/ij/).
Real-time PCR (real-time quantitative PCR)
Total RNA was prepared from frozen vaginal biopsies using Trizol/ chloroform extraction (Invitrogen, Paisley, UK), reverse transcribed into cDNA with SuperScript III RT (Invitrogen) and subjected to semiquantitative Real-Time quantitative PCR using iQSybr Green Supermix (Bio-Rad, Hercules, CA, USA) and primers for androgen receptor (AR) gene (Forward primer ¼ GCAGCAGCAGCGGGAGAG and Reverse primer ¼ CCTTGGCGTT GTCAGAAATGGTC) on iCycler (Bio-Rad) instrumentation and software. All PCR oligonucleotide primer pairs were designed using the Beacon Designer 2.0 software and were purchased from Integrated DNA Technologies (IDT, Leuven, Belgium). The DDCt method was used to calculate fold induction, and the Ct value of each gene was normalized with glyceraldehyde-3-phosphate dehydrogenase housekeeping gene (Forward ¼ GTGAAGCAGGCGTCGGAGG and Reverse ¼ CAAAGGTGGAGG AGTGGGTGTC).
Data analysis
Statistical analysis was performed using the SPSS 11. 0 software (SSPS, USA). Kruskal--Wallis test with Dunn's post hoc test was used to analyze the immunohistochemical results. One-way anova with post hoc Bonferroni test was used to analyze data from western blot and real-time PCR. A P value o0.05 was considered statistically significant.
RESULTS
Population characteristics and hormone levels are shown in Table 1 .
Immunohistochemistry
ARs were detected by immunostaining both in the mucosa and stroma of tissue biopsies collected from proximal and distal vagina, anterior and posterior, as shown in Figure 1 . In the vaginal mucosa, AR density score decreases with age (Po0.01) but does not change with T administration (Table 2) . In stromal tissue, AR density score does not change with age but significantly increases with T administration (Po0.01) ( Table 2 ). In PrM, AR expression was higher in the mucosa than in the stroma (Po0,001), whereas in M subjects it was higher in stromal tissue than in the mucosa (Po0,05) ( Table 2) . No difference in AR expression between Figure 2a . Protein expression was significantly increased in T-treated FtM subjects (Po0.01). AR protein expression in the distal portion of the vagina was not significantly different from the proximal portion, nor was any difference in protein expression detected between the anterior and posterior vaginal wall.
AR mRNA detection by real-time PCR The expression of AR mRNA, evaluated by quantitative Real-time PCR, showed a significantly higher mRNA expression in FtM versus M patients (Po0.01), and in PrM versus M subjects (Po0.01) (Figure 2b ). mRNA expression did not differ between FtM subjects and PrM subjects, and between proximal and distal, anterior and posterior walls within each group.
Correlation to body mass index and age Considering all vaginal samples from PrM and postmenopausal women together, a negative correlation between age and AR score was found only in vaginal mucosa (r ¼ À0.33; Po0.0001) Figure 3 , whereas no correlation was found when age and AR gene and protein expression from both mucosa and stroma were compared. No correlation was observed with body mass index.
DISCUSSION
In this study, we evaluated AR expression in the vaginal epithelium and stroma of PrM-, M-and T-treated subjects. We found AR protein and mRNA expression both in the epithelium and the stroma of the human vagina of PrM women with no significant differences between the proximal and distal, as well as the anterior and posterior, vaginal portions. A negative correlation was found between age and AR score in the vaginal epithelium but not in the stroma. T administration increased protein and mRNA expression in FtM subjects, reaching a statistical significance only at the protein level. After T administration, AR protein was found to be increased in the stroma but not in the epithelium.
To the best of our knowledge, this is the first study to report on AR gene expression and AR protein quantification and localization in the vagina of women of different ages and following T Testosterone and vaginal androgen receptor expression M Baldassarre et al treatment. In recent years, the addition of T to hormone replacement therapy or T administration alone has been proposed for treatment of postmenopausal women with hypoactive sexual desire. 16 Several preparations of androgens have been used in studies on treatment of female hypoactive sexual desire disorder and positive effects on various aspects of sexual function (increase in genital responsiveness, subjective reports of greater genital sensation and sexual desire) have been reported. 17 However, owing to the rather small extent of these effects and to uncertain long-term safety, there is a lack of consensus on whether this treatment should be proposed to women with hypoactive sexual desire disorder. In addition to its stimulatory effect on the brain regions involved in sexual response, T may also affect peripheral effectors of sexual response. Studies in animals have suggested that androgens regulate different physiological functions in the vagina such as mucification, nerve fiber density and vasodilatation. 19--21 The vagina is the key organ of female sexual response, and the understanding of androgen-induced modifications of this organ is important for tuning T-based hormonal treatment and to evaluate the safety of this strategy. 22 We detected AR protein in the human vagina with no difference between anterior and posterior walls, proximal and distal parts. In literature, only a few studies have documented the presence of AR in the human vagina, but data on distribution is inconsistent. Berman et al. 9 found a difference in concentration between the Mullerian (proximal) and the urogenital (distal) part of the vagina, whereas Ruizeveld de Winter et al. 23 did not find any difference between the two portions. We confirm the absence of different AR distribution among different parts of the vagina both in physiological status (PrM and M) and after T treatment. In agreement with previous reports, we found a negative correlation between age and AR density in the vaginal epithelium but not in the stroma. 9 In PrM, AR tended to be expressed more in the epithelium than in the stroma, but this difference disappeared and was even reversed with age, when AR decreased in the epithelium and remained stable in the stroma. This decrease of AR expression in the vaginal epithelium with age is in agreement with previous studies and may suggest a physiological role of T in the vagina during reproductive years, which is lost with age. 9 The physiological meaning of AR decline with age in the vaginal epithelium is unknown. T is known to regulate its own receptor in different tissues, 24, 25 and the decline in AR expression in menopause may reflect the lower circulating androgen level. This decline of AR would render the menopausal vagina even more insensitive to the lower circulating T, 2 and would explain the impaired sexual response of the menopausal vagina even in the presence of hormone replacement therapy.
AR expression following T administration has never been reported in humans. We found that in agreement with what happens in animals AR expression in the human vagina is also augmented by T administration. 5, 11 As in our patients T administration induced a decrease of E levels, 26 these observations may suggest a direct T-stimulatory effect on its own receptors not mediated by E. The AR increase, which we detected in the luteal phase when serum T levels are greater than those in the follicular phase, 27 and the decrease in menopause when T levels are also decreased may also confirm a direct influence of T serum levels on AR of the vagina as in other parts of female genitalia. 26 Increasing T levels result in increased sexual desire and arousal, and concomitantly augmented sensation and blood flow in the vagina has been reported. 5 The increase of AR, following increased T levels, may serve to magnify the effects of T and prepare the organ for sexual intercourse.
There are some limitations to this study. To evaluate the effects of T on the vaginal structure, we used a model of young women receiving T administration for sex reassignment. In these women, T concentrations reach levels well above the physiological levels in women and also above those found in women who receive T for hypoactive sexual desire disorder. Therefore, results of this study may not be found or may not be completely true in women with hypoactive sexual desire disorder treated with lower doses of T. In addition, we did not study inner portions of the vaginal layers such as muscular cells. Our biopsies did not include these cells, but certainly this layer may behave differently in terms of AR density and changes in response to the hormonal environment.
In conclusion, our study confirms the presence of AR in the human vagina, suggesting that the density of these receptors varies with phase of the cycle and age. We also found that a highdose T increases AR expression in human vaginal tissues. These data may suggest a direct effect of T on vaginal physiological regulation. Further studies are needed to understand the physiological role of T on these tissues.
